Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab and Chemotherapy in Newly Diagnosed Standard Risk or Down Syndrome B-ALL and Localized B-LLy
NCT03914625Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2019
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphoblastic lymphoma (B-LBL) (7 arms), sponsored by National Cancer Institute. Primary endpoint: Disease-Free Survival at 5.1 years. Started Jul 2019; status: active, not recruiting.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell lymphoblastic lymphoma (B-LBL)
Beyond the preview
Go deeper on NCT03914625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03914625.